Side Effects of Brolucizumab

Abstract Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome and provided an evolution in the tre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tahmineh Motevasseli, Saeed Mohammadi, Fatemeh Abdi, William R. Freeman
Formato:	article
Lenguaje:	EN
Publicado:	Knowledge E 2021
Materias:	anti-vascular endothelial growth factor brolucizumab wet age-related macular degeneration Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ac4e96759db54030b0e8016111a295ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac4e96759db54030b0e8016111a295ae
record_format	dspace
spelling	oai:doaj.org-article:ac4e96759db54030b0e8016111a295ae2021-11-09T08:05:35ZSide Effects of Brolucizumab2008-20102008-322X10.18502/jovr.v16i4.9757https://doaj.org/article/ac4e96759db54030b0e8016111a295ae2021-10-01T00:00:00Zhttps://doi.org/10.18502/jovr.v16i4.9757https://doaj.org/toc/2008-2010https://doaj.org/toc/2008-322XAbstract Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome and provided an evolution in the treatment of retinal disease. The current four anti-VEGF drugs – pegaptanib, ranibizumab, aflibercept, and bevacizumab – have been administered for many years. A new anti-VEGF agent, brolucizumab, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for the treatment of wet age-related macular degeneration. Brolucizumab is a novel single-chain fragment variable antibody that inhibits all isoforms of VEGF-A and has been suggested to have more tissue penetration. Despite all the benefits, there are some reports of serious side effects that need to be understood in managing patients. Brolucizumab has been reported to cause occlusive retinal vasculitis in the setting of intraocular inflammation, which has not been seen in other anti-VEGF medications. A PubMed and Scopus search was performed and all article types were included. In the present article, we have reviewed the reported side effects of brolucizumab.Tahmineh MotevasseliSaeed MohammadiFatemeh AbdiWilliam R. FreemanKnowledge Earticleanti-vascular endothelial growth factorbrolucizumabwet age-related macular degenerationOphthalmologyRE1-994ENJournal of Ophthalmic & Vision Research, Vol 16, Iss 4, Pp 670-675 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti-vascular endothelial growth factor brolucizumab wet age-related macular degeneration Ophthalmology RE1-994
spellingShingle	anti-vascular endothelial growth factor brolucizumab wet age-related macular degeneration Ophthalmology RE1-994 Tahmineh Motevasseli Saeed Mohammadi Fatemeh Abdi William R. Freeman Side Effects of Brolucizumab
description	Abstract Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome and provided an evolution in the treatment of retinal disease. The current four anti-VEGF drugs – pegaptanib, ranibizumab, aflibercept, and bevacizumab – have been administered for many years. A new anti-VEGF agent, brolucizumab, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for the treatment of wet age-related macular degeneration. Brolucizumab is a novel single-chain fragment variable antibody that inhibits all isoforms of VEGF-A and has been suggested to have more tissue penetration. Despite all the benefits, there are some reports of serious side effects that need to be understood in managing patients. Brolucizumab has been reported to cause occlusive retinal vasculitis in the setting of intraocular inflammation, which has not been seen in other anti-VEGF medications. A PubMed and Scopus search was performed and all article types were included. In the present article, we have reviewed the reported side effects of brolucizumab.
format	article
author	Tahmineh Motevasseli Saeed Mohammadi Fatemeh Abdi William R. Freeman
author_facet	Tahmineh Motevasseli Saeed Mohammadi Fatemeh Abdi William R. Freeman
author_sort	Tahmineh Motevasseli
title	Side Effects of Brolucizumab
title_short	Side Effects of Brolucizumab
title_full	Side Effects of Brolucizumab
title_fullStr	Side Effects of Brolucizumab
title_full_unstemmed	Side Effects of Brolucizumab
title_sort	side effects of brolucizumab
publisher	Knowledge E
publishDate	2021
url	https://doaj.org/article/ac4e96759db54030b0e8016111a295ae
work_keys_str_mv	AT tahminehmotevasseli sideeffectsofbrolucizumab AT saeedmohammadi sideeffectsofbrolucizumab AT fatemehabdi sideeffectsofbrolucizumab AT williamrfreeman sideeffectsofbrolucizumab
_version_	1718441233372676096

Side Effects of Brolucizumab

Ejemplares similares